Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed

What Was Tested

The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a randomized controlled trial.

The researchers calculated number needed to treat (NNT) and quarterly cost per responder (CPR) across four anti-CGRP mAbs.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got CGRP (Calcitonin Gene-Related Peptide) and who got the comparison, which limits bias.

As a double-blind CGRP (Calcitonin Gene-Related Peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.

Statistical comparisons were not made.

What Was Measured

Topics PubMed links to this paper include Migraine Disorders, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Numbers Needed To Treat, Calcitonin Gene-Related Peptide Receptor Antagonists and Randomized Controlled Trials as Topic.

The authors tagged it with the keywords Anti-CGRP, Cost per responder, Eptinezumab and Number needed to treat.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Advances in therapy), a journal based in United States.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.